Surgical Management of VHL-related Renal Cancers. Disclosures. Glossary. Overview. none

Similar documents
Challenges in RCC surgery. Treatment Goals. Surgical challenges. Management options in VHL associated RCCs

Who are Candidates for Laparoscopic or Open Radical Nephrectomy. Arieh Shalhav

Indications For Partial

10/11/2018. Clinical and Surgical Management of VHL-Related Cysts and Cystic RCC. Outline. VHL Renal Manifestations. VHL Renal Manifestations

RAPN. in T1b Renal Masses? A. Mottrie. G. Denaeyer, P. Schatteman, G. Novara

RCC in ADPKD / CKD / ESRD

Presentation of Cases /Audience Voting/Panel/Discussion

Vincenzo Ficarra 1,2,3. Associate Editor BJU International

Research Article Multifocal Renal Cell Carcinoma: Clinicopathologic Features and Outcomes for Tumors 4cm

What is the role of partial nephrectomy in the context of active surveillance and renal ablation?

Case Based Urology Learning Program

St. Dominic s Annual Cancer Report Outcomes

Comparison of Glomerular Filtration Rate (GFR) (RCC)

Renal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas San Antonio

Uro-Assiut 2015 Robotic Nephron Sparing Surgery

Salvage surgery after energy ablation for renal masses

Partial Nephrectomy Techniques for Renal Preservation: Historical and Modern Approaches

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?

When to Integrate Surgery for Metatstatic Urothelial Cancers

Index. Note: Page numbers of article titles are in boldface type.

Lymphadenectomy in RCC: Yes, No, Clinical Trial?

Complex case Presentations

Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute

Case Based Learning Program

Renal Tumors in Transplantation

Surgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology

Surgical strategy of bilateral synchronous sporadic renal cell carcinoma experience of a Chinese university hospital

Vincenzo Ficarra. Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine

Is renal cryoablation becoming an effective alternative to partial nephrectomy?

ELECTIVE PARTIAL NEPHRECTOMY FOR T1B RCC. Vitaly Margulis MD. Associate Professor of Urology

Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007

Small Renal Mass Guidelines. Clif Vestal, MD USMD Arlington, Texas

Management of Locally Reccurent Renal Cell Carcinoma. Jose A. Karam, MD, FACS Assistant Professor Department of Urology

Optimal Treatment of ct1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy?

Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma

NCCN AND AUA GUIDELINES FOR RCC:

Rapid communication chronic renal insufficiency after laparoscopic partial nephrectomy and radical nephrectomy for pathologic T1a lesions

Percutaneous Renal Cryoablation After Partial Nephrectomy: Technical Feasibility, Complications and Outcomes

Patient Selection for Ablative Therapies. Adrian D Joyce Leeds UK

Case Report Bilateral Renal Tumour as Indicator for Birt-Hogg-Dubé Syndrome

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management

Renal cryoablation of small renal masses: A Korea University experience

Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor

Case Report Staged, Open, No-Ischemia Nephron-Sparing Surgery for Bilateral-Multiple Kidney Tumors in a Patient with Birt-Hogg-Dubé Syndrome

Partial Nephrectomy Planning: Everybody s s doing it, you can to

EUROPEAN UROLOGY 61 (2012)

RENAL CANCER GUIDELINES

Partial Nephrectomy: Does Ischemia Matter?

IVC THROMBECTOMY: OPEN

Florida Cancer Specialist & Research Institute, Sebastian and Vero Beach, Fl, USA 3

Surgical Management of Pancreatic Cancer

Role of computed tomography-calculated intraparenchymal tumor volume in assessment of patients undergoing partial nephrectomy

Initial Clinical Experience with Robot-Assisted Laparoscopic Partial Nephrectomy for Complex Renal Tumors

Oncourology COMPLICATIONS OF PARTIAL NEPHRECTOMY AT OPERATIVE TREATMENT OF RENAL CELL CARCINOMA

Canadian Urological Association guidelines for followup of patients after treatment of nonmetastatic

Renal tumors of adults

Patient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.

Medical Management of Renal Cell Carcinoma

Measure Abbreviation: AKI 01 (QCDR Measure ID: ASPIRE19)

Università di Roma La Sapienza

NAACCR Webinar Series 1

Nephron-Sparing Surgery versus Radical Nephrectomy in the Treatment of Intracapsular Renal Cell Carcinoma up to 7 cm

Comparison of Partial and Radical Nephrectomy for pt1b Renal Cell Carcinoma

Effects of Partial Nephrectomy on Postoperative Blood Pressure

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Review Article Open Partial Nephrectomy in Renal Cancer: A Feasible Gold Standard Technique in All Hospitals

Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population

RECURRENT ADRENAL DISEASE. Megan Applewhite Endorama 2/19/2015 SR , SC

Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients

AUA Guidelines Renal Mass and Localized Kidney Cancer

Off-clamp robot-assisted partial nephrectomy for complex renal tumors

Supplementary Table 2. Surgical prophylaxis: Summary of selected series which included prophylactic management against the risk of bleeding.

Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Gerard M. Doherty, MD

The Incidental Renal Mass in the Primary Care Setting

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care

Complications in robotic surgery!! Review of the literature! RALP, RAPN and RARC!

Killing Tumors with Scans Not Scalpels: Kidney Cancer Ablation. Basics. What is Percutaneous Ablation? Where are your kidneys?

Evolution of Systemic Therapy Clinical Trials in VHL

Renal Mass Biopsy: Needed Now More than Ever

WHAT IS THE ROLE OF ACTIVE SURVEILLANCE

José Oberholzer, MD. Director Charles O. Strickler Transplant Center. Chief, Division of Transplantation

Case report. Open Access. Abstract

Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?

Fifteenth International Kidney Cancer Symposium

Disclosures. Neurological Manifestations of Von Hippel Lindau Syndrome. Objectives. Overview. None No conflicts of interest

Pancreatic Involvement in Von Hippel-Lindau Disease: The Role of Integrated Imaging

EVALUATION OF THE OUTCOME OF THE MANAGEMENT OF PATIENTS WITH RENAL CELL CARCINOMA

Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

GUIDELINES ON RENAL CELL CARCINOMA

Colon Cancer Liver Metastases: Liver-Directed Therapy

SURGERY, TRANSPLANTATION AND POLYCYSTIC DISEASE. Mr Nick Inston PhD FRCS Consultant Transplant Surgeon Queen Elizabeth Hospital Birmingham

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Long-Term Results of Simple Enucleation for the Treatment of Small Renal Cell Carcinoma

Hyeon Jun Jang, Wan Song, Yoon Seok Suh, U Seok Jeong, Hwang Gyun Jeon, Byong Chang Jeong, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Seong Il Seo

Introduction. Original Article: Clinical Investigation

Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer

Hereditary Leiomyomatosis and Renal Cell Carcinoma Variant of Reed s Syndrome - A Rare Case Report

Transcription:

Surgical Management of VHL-related Renal Cancers Disclosures Presentation to the VHL Family Alliance Annual Meeting, Denver, CO October 20, 2018 none Adam R. Metwalli, M.D. Professor & Chief, Division of Urology Howard University Hospital Director of Urologic Oncology Howard University Cancer Center Overview Background on VHL hereditary Renal Cancer Surgery Define terms Describe early history Describe surgical principles for VHL renal surgery Technical Aspects of Partial Nephrectomy Describe partial nephrectomy Margins Technical approaches Renal functional outcomes Impact of prolonged surgery on renal function Rationale for Aggressive Renal Surgery Glossary VHL - Von Hippel Lindau ccrcc clear cell renal cell carcinoma NSS - nephron sparing surgery PNx partial nephrectomy RNx radical nephrectomy BMF bilateral multifocal SRM Small Renal mass 1

Definitions Vast majority of RCC patients are unilateral, unifocal 4-25% who initially present unifocal, unilateral go onto develop multiple renal masses 1 Multifocal = >1 tumor in a single kidney 90% of multifocal are also bilateral 3-11% clinically detected; up to 25% on path 8,11-15 Papillary RCC seems to have highest incidence 6;7;16;17 Bilateral = at least 1 tumor in both kidneys >50% with bilateral tumors also multifocal 2-4 * Enucleation of the tumor: Cut out tumor leaving unaffected kidney tissue in place Definitions Wide Margin of Resection of the tumor: Remove a rim of unaffected kidney tissue surrounding the tumor (1) Walther MM, Lubensky IA, et al J Urol 1995 Dec;154(6):2010-4. (2) Klatte T, Wunderlich H, et al. BJU Int 2007 Jul;100(1):21-5. (3) Bratslavsky G, Linehan WM. Nature Reviews Urology 2010 May;7(5):267-75. (4) Wunderlich H, Schlichter A, et al. Urol Int 1999;63(3):160-3. (6) Lau WK, Blute ML, et al. Mayo Clin Proc 2000 Dec;75(12):1236-42. (7) Rabbani F, Herr HW, et al. J Clin Oncol 2002 May 1;20(9):2370-5. (8) Whang M, O'Toole K, et al. J Urol 1995 Sep;154(3):968-70. (11) Cheng WS, Farrow GM, et al. J Urol 1991;146:1221-3. (12) Minervini A, Serni S, et al. Eur J Surg Oncol 2009 May;35(5):521-6. (13) Mukamel E, Konichezky M, et al. J Urol 1988 Jul;140(1):22-4. (14) Nissenkorn I, Bernheim J. J Urol 1995 Mar;153(3 Pt 1):6 1995 Mar;153(3 Pt 1):6-2. (15) Rabbani F, McLoughlin MG. Can J Urol 1997 Sep;4(3):406-11. (16) Kletscher BA, Qian J, et al. J Urol 1995 Mar;153(3 Pt 2):904-6. (17) Dimarco DS, Lohse CM, et al. Urol 2004 Sep;64(3):462-7. VHL Renal Surgical History Early papers report risk of ccrcc in VHL of >70% Onset of renal tumors occurs earlier than non-hereditary RCC (40 vs 64) Original treatment paradigm for bilateral renal tumors bilateral RNx and transplant NSS surgery was pioneered as a reaction to this original treatment strategy Began in late 1980s early 1990s Hereditary Renal Cancer Despite controversy around partial nephrectomy, absolute indications exist Hereditary renal cancer Solitary kidney Bilateral tumors Long-term studies show similar oncologic outcomes regardless of radical vs partial nephrectomy for small renal masses Hereditary renal cancers present unique challenges 2

Hereditary Renal Cancer Phenotypes VHL mutation of VHL tumor suppressor gene on Chromosome 3, locus 3p25.1 Clear cell RCC (25-60% of affected patients) Pheochromocytoma Pancreatic cysts and neuroendocrine tumors CNS hemangioblastomas Cystadenomas (epididymis, mesosalpynx) Autosomal dominant Hereditary Renal Cancer Phenotypes VHL: Mother & Daughter VHL Surgical Principles 3 cm Rule -- Update Active surveillance 3cm rule enucleation Reset the clock --Unpublished data 3

VHL Growth Rate 240 tumors followed in 152 patients 1301 measurements made Median Growth rate was 3.7mm/yr Faster growth rate Male, youth No association between germline mutation or starting tumor size Higher risk of mets with higher diameter growth rate (7mm/yr vs 3.7mm/yr, p=0.01) Surgical Considerations --Unpublished data Surgical Margins in PNx DOGMA: 2cm margin 1cm margin Novick et al (Urology 2002, 60:993-997) Conclusion: width of resection margin after NSS does not correlate with long term disease progression. Fuhrman grade and TNM stage more important a millimeter is a mile = Not enough kidney left to function and avoid dialysis 4

Surgical Margins: do they matter? Published Data Literature review using nephron-sparing, partial nephrectomy, margin PSM = 0-7% in OPNx PSM = 0.7-4% in LPNx PSM = 3.9-5.7% in RPNx Complete tumor removal is the only factor PSM and high grade tumors increase risk of local recurrence Vast majority of patients will not recur despite PSM Frozen section offers little benefit over surgeons macroscopic assessment --Marszalek, M et al Eur Urol 2012 p757-763 Repeat PNx N=51, 19.6% major complication or reoperation mean Cr increased 1.16 to 1.35, egfr dropped from 95 to 85, 4% long term HD, median time to next surgery = 50mos, f/u=56mos Salvage PNx N=13, 46% major complications, 23% loss of kidney, no HD in those whose kidneys were preserved Creatinine : 1.2 1.4 egfr: 95 79 Repeat PNx solitary N-25 # tumors =4 median EBL=2400, OR time =8.5hrs 52% complications no significant difference in egfr at 1yr f/u 8 required repeat surgery median 36mos 95% metastasis free at 57mos 5

Post-RFA PNx N=13 median time from RFA to surgery was 2.75 yrs, #tumors=7 median EBL=1500 OR time 7.8hrs 75% op notes reported severe fibrosis, higher reoperation rate compared to repeat PNx series Cr=1 1.1; egfr= 91 81 low rate of visceral injury but 31% rate of pleural entry N=30pts & 34 operations 1 lost kidney median 26.5 tumors removed ebl=3500ml OR time =9hrs >50% complication rate, egfr=67 57 subsequent intervention at median of 52 months Long Story Short Minimally Invasive Published Data for Multifocal Renal Tumors Before each case AFTER each case 6

Robotic Partial Nephrectomy for Multiple, Complex masses Robotic Multiplex Partial Nephrectomy: Outcomes Multiplex Partial Nephrectomy (MxPNx). Kidney with 3 masses in complex locations Most commonly seen with hereditary renal cancer syndromes. Performed a retrospective analysis of patients that underwent Robotic partial nephrectomy at NIH from 2007-2013. Collected demographics, EBL, operative time, WIT, as well as perioperative creatinine and GFR. --Int J Urol Nephrol Nov 2016 Vol 48(11) pp1817-21 Robotic Multiplex Partial Nephrectomy 54 patients identified. Table 1. Patient Characteristics Table 1. Patient Characteristics VHL - 32 Mean Age (range) 46 (20 84) Gender Female % (n) 33 % (18) BMF - 11 BHD - 7 Male% (n) 66 % (36) HPRCC - 2 Race % (n) White 83% UMF - 1 AA 11% BMF PAP1 1 Asian 4% 77.8% with hereditary Latino 2% disorder. Mean ASA score (range) 2.96 (2 3) remainder have multifocal dz with an unknown Mean BMI (range) 30.5 (22.5 41.6) germline genetic alteration Estimated Preoperative GFR (SD) 85.4 (21.5) --Int J Urol Nephrol Nov 2016 Vol 48(11) pp1817-21 Robotic Multiplex Partial Nephrectomy Operative Characteristics: Table 2. Operative Characteristics Previous Surgery (mean) 1.63 (0.8) Operative side Right (%) 54% Left (%) 46% Conversion R-->O (n) 6 (11%) Partial--> Radical (n) 1 (1.8%) Number of masses (mean) 8.63 (8.9) EBL (SD) 1434mL (1475) Surgery time (SD) 385min (124) WIT (SD) 23.3min (6.4) Mean: 8.63±8.9 masses Minimum: 3.0 Maximum: 52 --Int J Urol Nephrol Nov 2016 Vol 48(11) pp1817-21 7

Robotic MxPNx Robotic to Open Conversion Robotic MxPNx Warm Ischemia WIT 10/54 cases: 18.5%. Number of masses removed: Mean 5.5 ± 2.64 (p=0.006) Med 4.5 Of the 10 cases on clamp: WIT: 23.3±6.4mins Min 15, max 37 29 --Int J Urol Nephrol Nov 2016 Vol 48(11) pp1817-21 Robot MxPNx Renal Function Outcomes Preoperative Pre- and egfr post-operative vs egfr 3months renal function Creatinine Mean P-Value Cr Preoperative 1.02±0.26 Cr post-op peak 1.47±0.53 p<0.016 Cr at 3-month follow-up 1.07±0.33 p=0.101 egfr Mean P-Value egfr Preoperative 85.4±21.5 egfr post-op nadir 60.8±24.3 p<0.031 egfr 3-month follow-up 82.3±24.0 p=0.21 A. B. 8/15/2014 1/8/2014 Figure 4. Representative MRI images pre and postoperatively. A. T1 weighted gadolinium-enhanced coronal MRI abdomen of right kidney pre-operatively on showing numerous multifocal renal tumors throughout the kidney. B. Right kidney post-operatively on T1 weighted gadolinium-enhanced MRI showing no renal tumors and post-operative changes. Note: RMxPNx peformed on 8/22/2014: 31 tumors excised, 2500cc EBL, 0min ischemia --Int J Urol Nephrol Nov 2016 Vol 48(11) pp1817-21 8

Methods Repeat Robotic Renal Surgery: Outcomes Identified patients who underwent complex multifocal partial nephrectomies: January 2007 and December 2013 2 ipsilateral renal or adrenal surgery, the second one being a RRPNx. Clinical characteristics, surgical parameters, complications and renal functional outcomes (preop and at 3 month f/u compared to patients undergoing initial ipsilateral robotic partial nephrectomy (irpnx). --J Endourol 2016 Vol 30(11) p1219-26 22 2 nd time Cases Results 124 Robotic Partial Nephrectomy 21% (26/124) RRPNx 4 3 rd time Cases 4 OPNx 1 Radical --J Endourol Vol 30(11) p1219-26 Results Patient Clincal Characteristics All irpnx RRPNx P value n 124 98 26 - Mean age 47.0±13.8 46.5±14.1 48.8±12.8 0.56 Mean BMI 30.1±5.5 30.1±7.4 30.1±5.2 0.90 Mean preop Cr mg/dl 0.97±0.3 0.96±0.27 1.02±0.27 0.27 Patient Operative Characteristics n All irpnx RRPNx P value n 124 98 26 - Mean Surgical 340.2±115.7 334.2±218.7 366.6±122.1 0.20 time (min) Mean EBL (cc) 930.7±1144.1 799±877.5 1426±1769 0.01 Mean # 4.5±7.1 4.6±7.4 4.3±7.8 tumors (1-52) (1-52) (1-29) resected 0.44 --J Endourol Vol 30(11) p1219-26 9

Analgesia requirements and Length of Hospital stay for irpnx vs RRPNx Complications irpnx vs RRPNx Patient Analgesia requirements and Length of Hospital stay irpnx RRPNx P value n 98 26 - Mean # days of IV pain medication Mean length of hospital stay (days) 2.4±01.7 2.9±2.0 0.316 5.4±2.7 7.1±2.9 0.001 --J Endourol Vol 30(11) p1219-26 --J Endourol Vol 30(11) p1219-26 Renal functional outcomes irpnx vs RRPNx Patient Renal Functional Outcomes irpnx RRPNx P value n 98 26 Mean Preop Cr (mg/dl) 0.96±0.2 1.02±0.27 0.27 Mean Cr 3 month f/u 1.06±0.38 1.17±0.37 0.06 (mg/dl) Mean % change Cr 10.9%±26.9% (Preop- to 16.7%±29.6% 0.69 3 month f/u) --J Endourol Vol 30(11) p1219-26 Standard PNx vs MxPNx in Solitary Kidney 93 patients, 121 surgical procedures 43 (35.5%) were SPNx 78 (64.4%) were MxPNx Total and Major complication rates were similar (57.1% vs 70.1% p=0.2)(31% vs 35.1% p=0.3) Renal function preservation was similar HD rate 4.7% vs 6.4% Completion Nx was similar Metastasis rate 8.6% vs 4.1% (p=0.4) --Unpublished data 10

OK. Your renal function outcomes are good but OR times are long and complications are high. Is it worth it?? Shortage of Transplantable Kidneys Wait list describe as a Darwinian ecosystem Most recent updates estimate nearly 350K on wait lists >50% have been on dialysis between 12-36mos BEFORE being listed More patients being removed from the lists within the first year Transplant rates per 1000 patient/year have decreased recently At 5 years, only 37% of listed patients are alive without transplant which is up from 22% -Gupta M and Abt PL, et al Am J Trans 2018 -Schold JD, Arrigain S, et al Am J Trans 2018 QOL on HD Numerous studies show lower QOL scores for individuals on HD Rationale for Pushing the Envelope Between 1989-2010 Repeat renal surgery patients at NCI evaluated Costs calculated for RRS 33 patients underwent RRS on solitary kidney Hypothetical cohort of uncomplicated nephrectomy, fistula placement, dialysis Medicare reimbursement --Agochukwu NQ, Metwalli AR et al J Urol 2012 p1695 11

Rationale for Pushing the Envelope 45% complication rate 87% maintained adequate renal function 96% metastasis-free Cost benefit realized at 0.68 years after surgery Benefit persists even calculating 50% underestimation of surgical costs HD cost estimated at $35,000/year ( 18421/year) Review Background on VHL hereditary Renal Cancer Surgery Define terms Describe early history Describe surgical principles for VHL renal surgery Technical Aspects of Partial Nephrectomy Describe partial nephrectomy Margins Technical approaches Renal functional outcomes Impact of prolonged surgery on renal function Rationale for Aggressive Renal Surgery Acknowledgements The End Dr. W. Marston Linehan Dr. Peter A. Pinto Dr. Piyush K. Agarwal Dr. Ram Srinivasan The UOB fellows The Georgetown residents The Walter Reed residents UOB staff Questions? 12